Hitt og þetta 30. júlí 2007

Total voting rights

London, UK: 30 July, 2007 - In conformity with the Transparency Directive's transitional provision 6, cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) notifies the market that the Company's issued share capital consists of 446,334,177 ordinary shares with voting rights. Antisoma does not hold any ordinary shares in Treasury. Therefore, the total number of voting rights in Antisoma is 446,334,177. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Antisoma under the FSA's Disclosure and Transparency Rules. - Ends - Enquiries: Raymond Spencer, CFO +44 (0)208 799 8200 Daniel Elger, Director of Communications Antisoma plc Background on Antisoma Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Please visit www.antisoma.com for further information about Antisoma. ---END OF MESSAGE---